In a small prospective study of obese individuals with known T2DM on stable doses of metformin and evidence of hepatic steatosis, those treated for 6 months with either liraglutide or the GLP-1 agonist exenatide demonstrated reduced hepatic steatosis and decreased liver enzyme levels [200]. This evidence concerns the gene GLP1R and Hepatic steatosis.